Most patients (45.6%) had hormone receptor (HR)-positive/Human epidermal growth factor receptor 2 (HER2)-negative tumors, and 22.8% had triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.